Side effects during chemotherapy predict tumour response in advanced colorectal cancer
Open Access
- 13 September 2005
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 93 (7) , 744-748
Abstract
To investigate whether a relationship between chemotherapy-associated adverse events and treatment efficacy exists, we have analysed the toxicity, objective response and survival data of 303 patients with advanced colorectal cancer. Patients were divided into two groups: the first with beneficial effect (I, n=245), and the second with progressive disease (II, n=58). Differences in terms of incidence rates, type and severity of adverse events were analysed with univariate and multivariate models. The median number of side effects in group I was 6 vs 4 in group II (OR=1.342; P=0.0001). An inverse correlation between disease control and treatment tolerance was confirmed when side effects were analysed according to severity and type of treatment-associated toxicities (haematological: P=0.0005 vs nonhaematological P=0.0001). When median survival was analysed according to the number of adverse events, it was 10 (95% CI, 3–7), 16 (14–18), and 18 (16–20) months in case of 0–1, 2–5, and 6 adverse events, respectively (P=0.01). In conclusion, the results of this analysis suggest that occurrence of side effects during chemotherapy in advanced colorectal cancer is an independent and reliable prognostic indicator for response and survival.Keywords
This publication has 24 references indexed in Scilit:
- Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of TreatmentJournal of Clinical Oncology, 2004
- Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2003
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorinAnnals of Oncology, 2002
- Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated mbc: updated results and analysis of dose modificationEuropean Journal of Cancer, 2001
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Colorectal cancerThe Lancet, 1999
- Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapyCancer Chemotherapy and Pharmacology, 1998
- Toxicity and Therapeutic Response to Chemotherapy in Patients Aged 70 Years or Older with Advanced CancerAmerican Journal of Clinical Oncology, 1996
- Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.BMJ, 1993
- Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.Journal of Clinical Investigation, 1988